20441T

14/23

薬物療法11） Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dose—dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high—risk operable breast cancer：a randomized phase Ⅲ study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005；16（11）：1762—71.［PMID：16148021］12） Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, et al. FEC versus sequential docetaxel followed by epirubicin／cyclophosphamide as adjuvant chemotherapy in women with axillary node—positive early breast cancer：a randomized study of the Hellenic Oncology Research Group（HORG）. Breast Cancer Res Treat. 2010；119（1）：95—104.［PMID：19636702］13） Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubi-cin plus cyclophosphamide as adjuvant chemotherapy for node—positive breast cancer：results from NSABP B—28. J Clin Oncol. 2005；23（16）：3686—96.［PMID：15897552］14） Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault—Llorca F, et al；UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node—positive breast cancer：the 8—year follow—up results of the UNICANCER—PACS01 trial. Oncologist. 2012；17（7）：900—9.［PMID：22610153］15） Roy C, Choudhury KB, Pal M, Saha A, Bag S, Banerjee C. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node—positive breast cancer. Indian J Cancer. 2012；49（3）：266—71.［PMID：23238142］16） Sakr H, Hamed RH, Anter AH, Yossef T. Sequential docetaxel as adjuvant chemotherapy for node—positive or／and T3 or T4 breast cancer：clinical outcome（Mansoura University）. Med Oncol. 2013；30（1）：457.［PMID：23322524］17） Forestieri V. Docetaxel in adjuvant therapy of breast cancer：results of the TAXIT 216 multicenter phase Ⅲ trial. Naples, University of Naples Federico II, 2008.18） Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, et al. TITAN：phase Ⅲ study of doxo-rubicin／cyclophosphamide followed by ixabepilone or paclitaxel in early—stage triple—negative breast cancer. Breast Cancer Res Treat. 2017；164（3）：649—58.［PMID：28508185］19） Ellis P, Barrett—Lee P, Johnson L, Cameron D, Wardley A, O’Reilly S, et al；TACT Trial Management Group；TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer（TACT）：an open—label, phase Ⅲ, randomised controlled trial. Lancet. 2009；373（9676）：1681—92.［PMID：19447249；PMCID：PMC2687939］20） Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, et al. Cyclophosphamide, epirubicin, and fluorouracil versus dose—dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node—positive or high—risk node—negative breast cancer. J Clin Oncol. 2010；28（1）：77—82.［PMID：19901117］CQ 7 91